Mastodon

Roxeptin (Tablets) Instructions for Use

ATC Code

J01FA06 (Roxithromycin)

Active Substance

Roxithromycin (Rec.INN WHO registered)

Clinical-Pharmacological Group

Antibiotic of the macrolide group

Pharmacotherapeutic Group

Antibiotic-macrolide

Pharmacological Action

A semisynthetic antibiotic of the macrolide group. The mechanism of action is due to the disruption of intracellular protein synthesis in microorganisms. At low concentrations, it has a bacteriostatic effect, at high concentrations – a bactericidal effect.

It is active against gram-positive bacteria: Streptococcus pneumoniae, Streptococcus pyogenes, methicillin-sensitive strains of Staphylococcus aureus; against gram-negative bacteria: Moraxella catarrhalis.

Roxithromycin is also active against Mycoplasma pneumoniae, Ureaplasma urealyticum, Chlamydia spp.

The activity of roxithromycin against Haemophilus influenzae is less pronounced than that of erythromycin.

It has low activity against Mycoplasma hominis.

Pseudomonas spp., Enterobacter spp., Acinetobacter spp. are resistant to roxithromycin.

Pharmacokinetics

After oral administration, it is rapidly absorbed from the gastrointestinal tract. It is detected in the blood serum as early as 15 minutes. It is more stable in the acidic environment of the stomach than other macrolides. Food intake does not affect absorption. Cmax in blood plasma is reached in 1.5-2 hours. Css in blood plasma when taking 150 mg 2 times/day is reached after 2-4 days and is 9.3 mg/l, when taking 300 mg 1 time/day – 10.9 mg/l.

Roxithromycin penetrates well into tissues, especially into the lungs, tonsils, and prostate, as well as into neutrophils and monocytes, stimulating their phagocytic activity. Plasma protein binding is 96%, decreasing with an increase in roxithromycin concentration above 4 mg/l. Less than 0.05% of the administered dose is excreted in breast milk.

It is partially metabolized in the liver, more than half of the active substance is excreted in the feces unchanged, about 12% is excreted by the kidneys and about 15% by the lungs. T1/2 in adults with normal renal function is 10.5 hours with a frequency of administration of 1-2 times/day.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to roxithromycin, including infections of the upper and lower respiratory tract, skin and soft tissue infections, non-gonococcal urethritis.

ICD codes

ICD-10 code Indication
J01 Acute sinusitis
J02 Acute pharyngitis
J03 Acute tonsillitis
J04 Acute laryngitis and tracheitis
J15 Bacterial pneumonia, not elsewhere classified
J15.7 Pneumonia due to Mycoplasma pneumoniae
J16.0 Pneumonia due to chlamydia
J20 Acute bronchitis
J31.0 Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis)
J31.2 Chronic pharyngitis
J32 Chronic sinusitis
J35.0 Chronic tonsillitis
J37 Chronic laryngitis and laryngotracheitis
J42 Unspecified chronic bronchitis
L01 Impetigo
L02 Cutaneous abscess, furuncle and carbuncle
L03 Cellulitis
L08.0 Pyoderma
L08.8 Other specified local infections of skin and subcutaneous tissue
N34 Urethritis and urethral syndrome
T79.3 Posttraumatic wound infection, not elsewhere classified
ICD-11 code Indication
1B70.1 Streptococcal cellulitis of the skin
1B70.2 Staphylococcal cellulitis of the skin
1B70.Z Bacterial cellulitis or lymphangitis caused by unspecified bacterium
1B72.0 Bullous impetigo
1B72.1 Nonbullous impetigo
1B72.Z Impetigo, unspecified
1B75.0 Furuncle
1B75.1 Carbuncle
1B75.2 Furunculosis
1B75.3 Pyogenic skin abscess
1B7Y Other specified pyogenic bacterial infections of skin or subcutaneous tissue
1C44 Non-pyogenic bacterial infections of skin
CA01 Acute rhinosinusitis
CA02.Z Acute pharyngitis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA05 Acute laryngitis or tracheitis
CA09.0 Chronic rhinitis
CA09.2 Chronic pharyngitis
CA0A.Z Chronic rhinosinusitis, unspecified
CA0F.Y Other specified chronic diseases of the palatine tonsils and adenoids
CA0G Chronic laryngitis or laryngotracheitis
CA20.1Z Chronic bronchitis, unspecified
CA40.00 Pneumonia due to Chlamydophila pneumoniae
CA40.04 Pneumonia due to Mycoplasma pneumoniae
CA40.0Z Bacterial pneumonia, unspecified
CA42.Z Acute bronchitis, unspecified
EA50.3 Staphylococcal scarlet fever
EB21 Pyoderma gangrenosum
GC02.Z Urethritis and urethral syndrome, unspecified
NF0A.3 Posttraumatic wound infection, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Tablets

Orally for adults – 150 mg 2 times/day (every 12 hours) or 300 mg 1 time/day 15 minutes before meals or on an empty stomach.

For patients with hepatic insufficiency, the dose is 150 mg every 24 hours.

For patients with severe renal insufficiency, the recommended dose is 150 mg every 24 hours.

For children, the daily dose is 5-8 mg/kg, depending on the type of pathogen and the severity of the infectious process, divided into 2 doses.

Adverse Reactions

From the digestive system: nausea, vomiting, epigastric pain, diarrhea, anorexia, flatulence, transient increase in the level of liver transaminases and alkaline phosphatase in the blood (more often in patients over 65 years old); rarely – liver function disorders, cholestatic hepatitis, pancreatitis.

Allergic reactions: urticaria, rash, itching, angioedema, bronchospasm, anaphylactoid reactions, tongue edema, general edema, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome.

From the central and peripheral nervous system: headache, dizziness, paresthesia.

Effects due to chemotherapeutic action: rarely – candidiasis.

Other: rarely – general malaise, tinnitus, taste and/or smell disturbances.

Contraindications

Severe liver dysfunction, simultaneous use of ergot alkaloids with vasoconstrictive effect, hypersensitivity to roxithromycin and other macrolides (including erythromycin).

Use in Pregnancy and Lactation

Adequate and strictly controlled studies on the safety of roxithromycin use during pregnancy and lactation have not been conducted.

Roxithromycin is excreted in small amounts in breast milk.

In experimental studies on animals, no mutagenic or embryotoxic effects, no negative effect on fertility were detected.

Use in Hepatic Impairment

Contraindicated in severe liver dysfunction. Use with caution in patients with mild to moderate liver dysfunction.

Use in Renal Impairment

Use with caution in patients with renal impairment.

Pediatric Use

Use is possible according to the dosage regimen.

Special Precautions

Use with caution in patients with impaired liver and kidney function.

If superinfection or pseudomembranous colitis develops, Roxithromycin should be discontinued immediately and appropriate therapy should be prescribed.

Use with caution simultaneously with terfenadine and astemizole.

In experimental studies, no carcinogenic effect was detected.

Drug Interactions

With simultaneous use with indirect anticoagulants, an enhancement of the anticoagulant effect is possible.

With simultaneous use with ergot preparations, ergotamine-like vasoconstrictors, the development of ergotism up to necrosis of limb tissues is possible.

With simultaneous use with digoxin, the absorption of digoxin increases.

With simultaneous use, a slight increase in the plasma concentrations of midazolam and triazolam is possible.

With simultaneous use with theophylline, an increase in the plasma concentration of theophylline is possible.

The possibility of an increase in plasma concentrations of cisapride, astemizole, terfenadine when used simultaneously with roxithromycin cannot be excluded.

With simultaneous use with cyclosporine, some increase in the blood concentration and toxic effect of cyclosporine is possible.

With simultaneous use with ethambutol, synergism against Mycobacterium avium is noted.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Ipca Laboratories Ltd. (India)

Dosage Form

Bottle Rx Icon Roxeptin Film-coated tablets, 150 mg: 10 or 50 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets 1 tab.
Roxithromycin 150 mg

10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (5) – cardboard packs.

Marketing Authorization Holder

Ipca Laboratories Ltd. (India)

Dosage Form

Bottle Rx Icon Roxeptin Dispersible tablets 50 mg: 10, 20 or 50 pcs.

Dosage Form, Packaging, and Composition

Dispersible tablets 1 tab.
Roxithromycin 50 mg

10 pcs. – strips (1) – cardboard packs.
10 pcs. – strips (2) – cardboard packs.
10 pcs. – strips (5) – cardboard packs.

TABLE OF CONTENTS